Neurofilaments May Not Be Biomarker for Older Patients

Neurofilaments May Not Be Biomarker for Older Patients

294105

Neurofilaments May Not Be Biomarker for Older Patients

The blood levels of neurofilaments — a marker of nerve cell damage — may serve as a disease onset and treatment response biomarker in infants with spinal muscular atrophy (SMA) type 1, but not in older patients with milder disease forms, a study suggests. These findings add to previous studies highlighting the absence of major differences in neurofilaments blood levels between older SMA patients and age-matched healthy individuals, and before and after treatment with Biogen’s Spinraza (nusinersen)…

You must be logged in to read/download the full post.